{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:41:43Z","timestamp":1787611303652,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1465-9921-12-129","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T18:17:19Z","timestamp":1317233839000},"source":"Crossref","is-referenced-by-count":23,"title":["Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial"],"prefix":"10.1186","volume":"12","author":[{"given":"Steven","family":"Kesten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartolome","family":"Celli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Decramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dacheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"key":"1150_CR1","volume-title":"Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO workshop report","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2001","unstructured":"Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO workshop report. 2001, Bethesda, MD: National Heart, Lung and Blood Institute, (revised December 2009), (accessed 13 August 2010), [ http:\/\/www.goldcopd.org ]"},{"key":"1150_CR2","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1136\/bmj.1.6077.1645","volume":"1","author":"C Fletcher","year":"1977","unstructured":"Fletcher C, Peto R: The natural history of chronic airflow obstruction. Br Med J. 1977, 1: 1645-1648. 10.1136\/bmj.1.6077.1645.","journal-title":"Br Med J"},{"key":"1150_CR3","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1001\/jama.1994.03520190043033","volume":"272","author":"NR Anthonisen","year":"1994","unstructured":"Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P, et al: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J Am Med Assoc. 1994, 272: 1497-1505. 10.1001\/jama.272.19.1497.","journal-title":"J Am Med Assoc"},{"key":"1150_CR4","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, for the UPLIFT investigators: A four year trial of tiotropium in patients with chronic obstructive pulmonary disease. N Engl J Med. 2008, 359: 1543-1554. 10.1056\/NEJMoa0805800.","journal-title":"N Engl J Med"},{"key":"1150_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1081\/COPD-200026934","volume":"1","author":"M Decramer","year":"2004","unstructured":"Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, Cassino C, Kesten S: Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD. 2004, 1: 303-312. 10.1081\/COPD-200026934.","journal-title":"COPD"},{"key":"1150_CR6","doi-asserted-by":"crossref","unstructured":"Standardization of spirometry - 1994 update. American Thoracic Society. Am J Respir Crit Care Med. 1995, 152: 1107-1136.","DOI":"10.1164\/ajrccm.152.3.7663792"},{"key":"1150_CR7","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","volume":"145","author":"PW Jones","year":"1992","unstructured":"Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis. 1992, 145: 1321-1327.","journal-title":"Am Rev Respir Dis"},{"key":"1150_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.7326\/0003-4819-99-5-612","volume":"99","author":"IPPB Trial Group","year":"1983","unstructured":"IPPB Trial Group: Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease. Ann Intern Med. 1983, 99: 612-620.","journal-title":"Ann Intern Med"},{"key":"1150_CR9","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1164\/ajrccm\/140.3_Pt_2.S95","volume":"140","author":"NR Anthonisen","year":"1989","unstructured":"Anthonisen NR: Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials. Am Rev Resp Dis. 1989, 140: S95-S99. 10.1164\/ajrccm\/140.1.95.","journal-title":"Am Rev Resp Dis"},{"key":"1150_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa021322","volume":"350","author":"BR Celli","year":"2004","unstructured":"Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Eng J Med. 2004, 350: 1005-1012. 10.1056\/NEJMoa021322.","journal-title":"N Eng J Med"},{"key":"1150_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1164\/rccm.200901-0047OC","volume":"180","author":"R Kohansal","year":"2009","unstructured":"Kohansal R, Matinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB: The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Resp Crit Care Med. 2009, 180: 3-10. 10.1164\/rccm.200901-0047OC.","journal-title":"Am J Resp Crit Care Med"},{"key":"1150_CR12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","volume":"178","author":"BR Celli","year":"2008","unstructured":"Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008, 178: 332-338. 10.1164\/rccm.200712-1869OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1150_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","volume":"57","author":"GC Donaldson","year":"2002","unstructured":"Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002, 57: 847-852. 10.1136\/thorax.57.10.847.","journal-title":"Thorax"},{"key":"1150_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1164\/ajrccm.164.3.2010017","volume":"164","author":"RE Kanner","year":"2001","unstructured":"Kanner RE, Anthonisen NR, Connett JE: Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001, 164: 358-364.","journal-title":"Am J Respir Crit Care Med"},{"key":"1150_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/thx.2005.040527","volume":"60","author":"JJ Soler-Cataluna","year":"2005","unstructured":"Soler-Cataluna JJ, Martinez-Garcia MA, Rom\u00e1n S\u00e1nchez P, Salcedo E, Navarro M, Ochando R: Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005, 60: 925-993. 10.1136\/thx.2005.040527.","journal-title":"Thorax"},{"key":"1150_CR16","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1056\/NEJM200012283432601","volume":"343","author":"The Lung Health Study Research Group","year":"2000","unstructured":"The Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000, 343: 1902-9.","journal-title":"N Engl J Med"},{"key":"1150_CR17","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","volume":"340","author":"RA Pauwels","year":"1999","unstructured":"Pauwels RA, L\u00f6fdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999, 340: 1948-1953. 10.1056\/NEJM199906243402503.","journal-title":"N Engl J Med"},{"key":"1150_CR18","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","volume":"320","author":"PS Burge","year":"2000","unstructured":"Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J. 2000, 320: 1297-1303. 10.1136\/bmj.320.7245.1297.","journal-title":"Br Med J"},{"key":"1150_CR19","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","volume":"365","author":"M Decramer","year":"2005","unstructured":"Decramer M, Rutten-van M\u00f6lken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A: Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005, 365: 1552-1560. 10.1016\/S0140-6736(05)66456-2.","journal-title":"Lancet"},{"key":"1150_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1183\/09031936.00082909","volume":"35","author":"DP Tashkin","year":"2010","unstructured":"Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S, Decramer M: Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Resp J. 2010, 35: 287-294. 10.1183\/09031936.00082909.","journal-title":"Eur Resp J"},{"key":"1150_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, the TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med. 2007, 356: 775-789. 10.1056\/NEJMoa063070.","journal-title":"N Eng J Med"},{"key":"1150_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1183\/09031936.00127809","volume":"36","author":"T Troosters","year":"2010","unstructured":"Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M, UPLIFT Investigators: Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Resp J. 2010, 36: 65-73. 10.1183\/09031936.00127809.","journal-title":"Eur Resp J"},{"key":"1150_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1183\/09031936.00103008","volume":"32","author":"S Suissa","year":"2008","unstructured":"Suissa S: Lung function decline in COPD trials: bias from regression to the mean. Eur Resp J. 2008, 32: 829-831. 10.1183\/09031936.00103008.","journal-title":"Eur Resp J"},{"key":"1150_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1378\/chest.07-3059","volume":"134","author":"SI Rennard","year":"2008","unstructured":"Rennard SI, Vestbo J: The many \"small COPDs\": COPD should be an orphan disease. Chest. 2008, 134: 623-627. 10.1378\/chest.07-3059.","journal-title":"Chest"},{"key":"1150_CR25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMe0807387","volume":"359","author":"JJ Reilly","year":"2008","unstructured":"Reilly JJ: COPD and declining FEV1 - time to divide and conquer?. N Eng J Med. 2008, 359: 1616-1618. 10.1056\/NEJMe0807387.","journal-title":"N Eng J Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-12-129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1465-9921-12-129\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-12-129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T07:07:17Z","timestamp":1497942437000},"score":1,"resource":{"primary":{"URL":"http:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/1465-9921-12-129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1186\/1465-9921-12-129","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"article-number":"129"}}